MAPT and amyloidosis: When injecting AD-tau into an amyloid-murine model, chronic activation of TREM2 with an activating TREM2 antibody increased amyloid load and tau-phosphorylation, indicating that chronic activation of TREM2 in late-stage AD may exacerbate the disease [13].